Products
IntegriChain’s Data and Technology Products
Bringing together data science and advanced analytics with highly-scalable and sophisticated applications to tackle today’s most challenging and complex drug commercialization processes.
ICyte, IntegriChain’s market access platform, leverages data to help pharma manufacturers manage and scale contracts, pricing, gross-to-net modeling, patient access, and more. To learn more about how ICyte can apply to your pharmaceutical commercialization processes, contact our sales and consulting team today.
Channel
Government Pricing
IntegriChain’s Government Pricing provides all relevant calculations required for the Medicaid, Medicare, PHS, and FSS programs. Delivered via the ICyte Platform, our Government Pricing services are expertly designed with robust data cleansing and standardization, an automated data load process, and comprehensive and auditable control reports covering all price calculation details.
Rebate Management
Rebate Management solutions allow our customers to scale their payer analytics and contracting functions to meet today’s complex commercial and government access challenges. From managed care to Medicaid and other governmental rebates, IntegriChain is the leading provider of claims adjudication, handling all of your needs for your claims payments and rebate processing within the ICyte Platform.
Chargeback Management
IntegriChain’s Chargeback Management solutions offer a full suite of chargeback reconciliation and analytics capabilities across GPO/IDN provider and federal contracts such as 340B and FSS. Delivered via the ICyte Platform, our offerings marry expert contract management and unparalleled chargeback processing, uniquely processing the most comprehensive set of validity checks and delivering operational reporting and wholesaler scorecards to better manage your programs.
Script Management
IntegriChain’s Script Management solutions provide cross-channel pharma data retrieval, scrubbing, validation, and reconciliation at scale. Delivered via the ICyte Platform, our combination of AI-driven automation and data science enables in-line dispute management instead of a costly “pay-and-chase” approach that contributes to revenue leakage.
Contracts & Pricing Resources
Webinar
Updated Review and Interpretation of the Inflation Reduction Act
Jeff Baab spoke on a panel at Contracts & Pricing USA with Endo Pharmaceuticals, providing a refresher overview of the Inflation Reduction Act and how it will affect you and your company – both for commercial and GP department.
Listen to the Recording
Case Study
Big Pharma Conversion of Legacy Revenue Management to Innovative ICyte SaaS Platform
IntegriChain was approached by a top-15 pharma manufacturer with 39 in-line therapies covering 73 indications and an additional 12 drugs in phase 3 clinical trials. Most recently, their legacy portfolio is facing significant public policy pressure.
READ The Case Study
GTN Accruals
GTN Accruals is a scalable application designed to simplify the management of accruals. Delivered via the ICyte Platform, it is configured for all standard GTN line items with robust out-of-the-box accrual methodologies. The prior period true-up functionality, inventory pipeline adjustments to accruals, and balance sheet roll-forward and reconciliations reduce error-prone, manual work while also enabling faster close and easier audit preparation.
GTN Forecasting
Forecasting accruals is a challenge for every Finance and Market Access team. IntegriChain’s GTN Forecasting solutions makes easy work of delivering consistent, documented, and transparent forecasts, all built around industry-proven methodologies and complete with robust pricing scenario modeling capabilities.
GTN Analytics
GTN Analytics rounds out our GTN automation suite of products and complements our GTN Accruals and GTN Forecasts solutions. By offering data access and analytics in a single system of truth and forecast accuracy, we can help you improve management confidence in your data through GTN automation.
Learn More
Gross-to-Net Resources
Webinar
Gross-To-Net Considerations for Launching Specialty and Specialty-Lite Products
The growth of specialty and specialty-lite drugs means that manufacturers have to contend with channel design and pricing challenges as they approach commercialization and beyond.
WATCH THE WEBINAR
Case Study
Driving Gross-to-Net Excellence and Portfolio Expansion in Mid-Market Pharma
Learn more about a pharma manufacturers overcoming challenges when launching into a new therapeutic category.
Channel Data Solutions
Our Channel Data Solutions aggregate all your channel data sets, including distributor sales, distributor inventory, specialty pharmacy inventory, and product returns. By consolidating all of this data on the ICyte Platform, you can achieve better end-to-end view of your direct, wholesale, and specialty distribution, insight into inventory availability risks, provide the highest quality data to sensitive gross- to-net accrual and incentive compensation processes, and monitor product launch progress and inventory availability at the individual retail pharmacy level.
Inventory Analytics
Manufacturers have few existing measures of the inventory held in retail stores, distribution centers, and third-party returns processors. IntegriChain’s Inventory Analytics reports 100% of inventory in the retail channel, even in pharmacy stores and distribution centers that do not report their inventories.
Distribution Contract Management
Distribution Contract Management is a single, auditable application for managing all aspects of trade partner agreements. Configurable trade partner scorecard functionality features payment adjudication, custom pay-for-performance metrics, payment roll forward, and top- and bottom-line functionality adjustments. These functions are automated and facilitate standardized contract negotiations with trade partners. Manufacturers can also monitor trade partner purchase orders in real time and make decisions based on channel inventory and order quantity.
Order Management
IntegriChain Order Management offers real-time control of purchase orders against user-configured business rules and an exceptions-based workflow for quickly investigating and resolving issues. Order Management allows manufacturers to hold questionable orders, review orders against DOH guardrails, calculate minimum/maximum order units, and monitor suspicious order quantities.
Channel Resources
Blog
Thoughts Following Asembia 2023 Part 1: Exploring the New Pharmacy Landscape
Channel expert Bill Roth explores how specialty pharmacy has evolved and their take on the current landscape and insights from pharmaceutical manufacturers.
READ THE BLOG
Case Study
Comprehensive Channel and Payer Contracting at Top-10 Pharma Manufacturer
This customer is one of the world’s largest Pharmaceutical manufacturers with 76 in-line drugs covering more than 100 conditions across 10 therapeutic categories and another dozen drugs in phase 3 clinical trials.
Patient Data Solutions
Patient Data Solutions leverage IntegriChain’s industry-leading patient mastering and master data management technology to aggregate and ensure the accuracy and actionability of patient status data, provide more timely visibility pharmacies, and more accurately measure the impact of patient service programs on patient initiation and adherence.
Specialty Pharmacy Analytics
IntegriChain’s Specialty Pharmacy Analytics delivers diagnostic patient journey insights by calibrating the datasets associated with a suite of business KPIs and analytics to reflect the uniqueness of your brand’s patient access. Our diagnostic analytics for patient initiation, therapy adherence, field reimbursement, hub services, and patient services go a level deeper to uncover the reasons why your patients are struggling to overcome barriers along the patient journey.
Patient Access Resources
Case Study
Creating the Access Backbone for Leading Rare Disease Portfolio
This customer had three in-line therapies across Immunology, Hematology, and Infectious Disease with another five therapies in phase III clinical trials, driving the need for more aggressive commercial contracting.
READ THE CASE STUDY
Blog
Best Practices: Identifying and Avoiding Patient Access Barriers
Adapted from IntegriChain’s 2021 Access Insights Conference panel session: Best Practices for Launch featuring DBV Technologies, Karyopharm Therapeutics, and Sesen Bio.